PharmaPoint: Age-Related Macular Degeneration – Global Drug Forecast and Market Analysis to 2026

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

There are two clinical forms of age-related macular degeneration (AMD): dry and wet. Currently there are therapies available only for wet AMD. Drugs in late stages of development target the wet AMD segment and the late stage or atrophic form of dry AMD, called geographic atrophy (GA). The global markets are currently overwhelmingly dominated by anti-VEGFs for wAMD, including Lucentis, Eylea, and Avastin, which together accounted for 99.3% of AMD sales. Visudyne, photodynamic therapy (PDT), is used in a minority of patients usually combined with an anti-VEGF.
The AMD pipeline is strong, with two longer-acting anti-VEGF drugs (Novartis/Alcon’s brolucizumab and Allergan’s abicipar pegol) and two add-on therapies (Ohr’s squalamine and Opthea’s OPT-302) in late-stage clinical development (Phase IIb/III) for wet AMD. Four drugs are in the late pipeline for GA, three complement inhibitors (Roche’s lampalizumab, Ophthotech’s Zimura, and Apellis’ APL-2) and a cyto/neuroprotective agent (Allergan’s Brimo DDS), which could launch within the forecast period.
GlobalData estimates the 2016 sales for AMD at approximately $4.9B across the 7MM covered in this report. The AMD market will experience a significant growth during the forecast period at a CAGR of 13.4%, with global sales of $17.3B in 2026. Such rapid growth is due primarily to the introduction of the new therapies for the previously untreatable dry AMD patients with GA, the launch of add-on therapies for wet AMD, and the increasing prevalence of AMD as a result of aging societies.

Scope

Overview of AMD, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.

Annualized AMD therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in two patient segments (GA due to dry AMD and wet AMD), forecast from 2016 to 2026.

Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the AMD therapeutics market.

Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for AMD therapy. The most promising candidates in Phase IIb and Phase III developments are profiled.

Analysis of the current and future market competition in the global AMD therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Key Highlights

What are the key drivers of significant growth of the AMD market?

How the sales of the current market leader, Bayer’s Eylea, will be affected by the launch of longer-acting anti-VEGF therapies (brolucizumab and abicipar pegol)?

How would physicians fit squalamine and OPT-302 add-on therapies into the wet AMD treatment algorithm and what are their pricing and reimbursement prospects?

What are the market potentials of drugs developed for the treatment of GA associated with dry AMD, and would they fulfil the greatest unmet need in this space?

How will key patent expiries of anti-VEGF therapies and the use of Avastin impact sales of current and launching therapies in wet AMD?

Will there be opportunities remaining after the launch of late pipeline drugs in wet AMD and dry AMD?

Reasons to Buy

The report will enable you to:

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the global AMD therapeutics market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global AMD therapeutics market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Roche
Genentech
Novartis
Alcon
Regeneron
Bayer
Valeant
Allergan
Ohr
Ophthotech
Apellis
Opthea
Chugai
Pfizer
Santen
PanOptica
SciFluor Life Sciences
Tyrogenex
RXi Pharmaceuticals
Janssen
Astellas Pharma

Table of Contents

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Age-Related Macular Degeneration: Executive Summary

2.1 Significant Growth Expected in the AMD Market from 2016 to 2026

2.2 R&D and Corporate Strategies Within the AMD Market

2.3 Current Therapies for AMD Leave Abundant Unmet Needs

2.4 Opportunities Will Remain for New Entrants

2.5 Late-Stage Pipeline Drugs Entering the AMD Market Will Be a Key Driver of Growth

2.6 What Do Physicians Think?

3 Introduction

3.1 Catalyst

3.2 Related Reports

3.3 Upcoming Related Reports

4 Disease Overview

4.1 Etiology and Pathophysiology

4.1.1 Overview

4.1.2 dAMD

4.1.3 wAMD

4.1.4 Genetic Targets of Interest

4.2 Classification

4.3 Symptoms

4.4 Prognosis

5 Epidemiology

5.1 Disease Background

5.2 Risk Factors and Comorbidities

5.3 Global and Historical Trends

5.4 Forecast Methodology

5.4.1 Sources Used

5.4.2 Forecast Assumptions and Methods

5.4.3 Total Prevalent Cases of AMD, Early AMD, Late AMD, Late Dry AMD, Late Wet AMD, and Large Drusen

5.4.4 Diagnosed Incident Cases of AMD, Early AMD, Late AMD, Late Dry AMD, Late Wet AMD, and Large Drusen

5.5 Epidemiological Forecast for AMD (2016–2026)

5.5.1 Total Prevalent Cases of AMD

5.5.2 Age-Specific Total Prevalent Cases of AMD

5.5.3 Sex-Specific Total Prevalent Cases of AMD

5.5.4 Total Prevalent Cases of Early AMD

5.5.5 Total Prevalent Cases of Late AMD

5.5.6 Total Prevalent Cases of Late Dry AMD

5.5.7 Total Prevalent Cases of Late Wet AMD

5.5.8 Total Prevalent Cases of Large Drusen

5.5.9 Diagnosed Incident Cases of AMD

5.5.10 Age-Specific Diagnosed Incident Cases of AMD

5.5.11 Sex-Specific Diagnosed Incident Cases of AMD

5.5.12 Diagnosed Incident Cases of Early AMD

5.5.13 Diagnosed Incident Cases of Late AMD

5.5.14 Diagnosed Incident Cases of Late Dry AMD

5.5.15 Diagnosed Incident Cases of Late Wet AMD

5.5.16 Diagnosed Incident Cases of Large Drusen

5.6 Discussion

5.6.1 Epidemiological Forecast Insight

5.6.2 Limitations of the Analysis

5.6.3 Strengths of the Analysis

6 Disease Management

6.1 Diagnosis Overview

6.2 Treatment Overview

6.2.1 Treatment Guidelines and Leading Prescribed Drugs

6.2.2 Clinical Practice

6.2.3 dAMD

6.2.4 wAMD

7 Competitive Assessment

7.1 Overview

7.2 Lucentis (Ranibizumab)

7.2.1 Overview

7.2.2 Efficacy

7.2.3 Safety

7.2.4 Forecast

7.3 Avastin (Bevacizumab)

7.3.1 Overview

7.3.2 Efficacy

7.3.3 Safety

7.3.4 SWOT Analysis

7.3.5 Forecast

7.4 Eylea (Aflibercept)

7.4.1 Overview

7.4.2 Efficacy

7.4.3 Safety

7.4.4 SWOT Analysis

7.4.5 Forecast

7.5 Macugen (Pegaptanib Sodium)

7.5.1 Overview

7.5.2 Efficacy

7.5.3 Safety

7.6 Visudyne (Verteporfin)

7.6.1 Overview

7.6.2 Efficacy

7.6.3 Safety

7.6.4 SWOT Analysis

7.6.5 Forecast

8 Unmet Needs and Opportunity Assessment

8.1 Overview

8.2 Treatment for Dry AMD

8.2.1 Unmet Need

8.2.2 Gap Analysis

8.2.3 Opportunity

8.3 Longer Acting Therapy

8.3.1 Unmet Need

8.3.2 Gap Analysis

8.3.3 Opportunity

8.4 Increased Anti-VEGF Efficacy

8.4.1 Unmet Need

8.4.2 Gap Analysis

8.4.3 Opportunity

8.5 Less Invasive Formulations

8.5.1 Unmet Need

8.5.2 Gap Analysis

8.5.3 Opportunity

8.6 Early Diagnosis and Disease Management

8.6.1 Unmet Need

8.6.2 Gap Analysis

8.6.3 Opportunity

9 Pipeline Assessment

9.1 Overview

9.2 Clinical Trial Mapping

9.2.1 Clinical Trials by Patient Population

9.3 Promising Drugs in Clinical Development

9.3.1 Brolucizumab

9.3.2 Abicipar pegol

9.3.3 OPT-302

9.3.4 Squalamine

9.3.5 Lampalizumab

9.3.6 Zimura

9.3.7 APL-2

9.3.8 Brimo DDS

9.4 Promising Drugs in Early-Stage Development

9.4.1 Complement Inhibitors

9.4.2 Anti-Angiogenic Agent

9.4.3 Anti-angiogenic (Topical)

9.4.4 Anti-angiogenic (Oral)

9.4.5 Anti-Fibrotic Agent

9.4.6 Stem Cell Therapy

9.5 Other Drugs in Development

9.6 Biosimilars

10 Current and Future Players

10.1 Overview

10.2 Trends in Corporate Strategy

10.3 Roche/Genentech

10.3.1 Overview

10.3.2 Portfolio Assessment

10.4 Novartis/Alcon

10.4.1 Overview

10.4.2 Portfolio Assessment

10.5 Regeneron

10.5.1 Overview

10.5.2 Portfolio Assessment

10.6 Bayer

10.6.1 Overview

10.6.2 Portfolio Assessment

10.7 Valeant

10.7.1 Overview

10.7.2 Portfolio Assessment

10.8 Allergan

10.8.1 Overview

10.8.2 Portfolio Assessment

10.9 Ohr Pharmaceutical

10.9.1 Overview

10.9.2 Portfolio Assessment

10.10 Ophthotech

10.10.1 Overview

10.10.2 Portfolio Assessment

10.11 Apellis

10.11.1 Overview

10.11.2 Portfolio Assessment

10.12 Opthea

10.12.1 Overview

10.12.2 Portfolio Assessment

11 Market Outlook

11.1 Global Markets

11.1.1 Forecast

11.1.2 Drivers and Barriers – Global Issues

11.2 US

11.2.1 Forecast

11.2.2 Key Events

11.2.3 Drivers and Barriers

11.3 5EU

11.3.1 Forecast

11.3.2 Key Events

11.3.3 Drivers and Barriers

11.4 Japan

11.4.1 Forecast

11.4.2 Key Events

11.4.3 Drivers and Barriers

12 Appendix

12.1 Bibliography

12.2 Abbreviations

12.3 Methodology

12.3.1 Forecasting Methodology

12.3.2 Diagnosed Patients

12.3.3 Percent Drug-Treated Patients

12.3.4 Drugs Included in Each Therapeutic Class

12.3.5 General Pricing Assumptions

12.3.6 Individual Drug Assumptions

12.3.7 Generic Erosion

12.3.8 Pricing of Pipeline Agents

12.4 Primary Research – KOLs Interviewed for This Report

12.5 Primary Research – Prescriber Survey

12.6 About the Authors

12.6.1 Analyst

12.6.2 Therapy Area Director

12.6.3 Epidemiologist

12.6.4 Managing Epidemiologist

12.6.5 Global Director of Therapy Analysis and Epidemiology

12.6.6 Global Head and EVP of Healthcare Operations and Strategy

12.7 About GlobalData

12.8 Contact Us

12.9 Disclaimer

Table

Table 1: AMD: Key Metrics in the 7MM

Table 2: Biological Pathways Associated with AMD Risk Genes

Table 3: The Four-Stage AREDS Classification of AMD

Table 4: Symptoms of AMD

Table 5: Severity Scale to Assess Five-Year Risk of Progression to Advanced AMD

Table 6: Risk Factors and Comorbid Conditions Associated with AMD

Table 7: Classification of AMD

Table 8: 7MM, Total Prevalent Cases of AMD, Both Sexes, Ages ≥50 Years, N, Selected Years 2016–2026

Table 9: 7MM, Total Prevalent Cases of Early AMD, Both Sexes, Ages ≥50 Years, N, Selected Years 2016–2026

Table 10: 7MM, Total Prevalent Cases of Late AMD, Both Sexes, Ages ≥50 Years, N, Selected Years 2016–2026

Table 11: 7MM, Total Prevalent Cases of Late Dry AMD, Both Sexes, Ages ≥50 Years, N, Selected Years 2016–2026

Table 12: 7MM, Total Prevalent Cases of Late Wet AMD, Both Sexes, N, Ages ≥50 Years, Selected Years 2016–2026

Table 13: 7MM, Total Prevalent Cases of Large Drusen, Both Sexes, Ages ≥50 Years, N, Selected Years 2016–2026

Table 14: 7MM, Diagnosed Incident Cases of AMD, Both Sexes, Ages ≥50 Years, N, Selected Years 2016–2026

Table 15: 7MM, Diagnosed Incident Cases of Early AMD, Both Sexes, Ages ≥50 Years, N, Selected Years 2016–2026

Table 16: 7MM, Diagnosed Incident Cases of Late AMD, Both Sexes, Ages ≥50 Years, N, Selected Years 2016–2026

Table 17: 7MM, Diagnosed Incident Cases of Late Dry AMD, Both Sexes, Ages ≥50 Years, N, Selected Years 2016–2026

Table 18: 7MM, Diagnosed Incident Cases of Late Wet AMD, Both Sexes, Ages ≥50 Years, N, Selected Years 2016–2026

Table 19: 7MM, Diagnosed Incident Cases of Large Drusen, Both Sexes, Ages ≥50 Years, N, Selected Years 2016–2026

Table 20: Treatment Guidelines for AMD

Table 21: AMD Disease Management – US

Table 22: AMD Disease Management – 5EU

Table 23: AMD Disease Management – Japan

Table 24: Most Prescribed Drugs for AMD in the Global Markets, 2017

Table 25: Product Profile – Lucentis

Table 26: Lucentis SWOT Analysis, 2017

Table 27: Product Profile – Avastin

Table 28: Avastin SWOT Analysis, 2017

Table 29: Product Profile – Eylea

Table 30: Eylea — Common Adverse Reactions

Table 31: Eylea SWOT Analysis, 2017

Table 32: Product Profile – Macugen

Table 33: Product Profile – Visudyne

Table 34: Visudyne SWOT Analysis, 2017

Table 35: Comparison of Therapeutic Classes in Development for AMD, 2016–2026

Table 36: Product Profile – Brolucizumab

Table 37: Brolucizumab and Eylea — Ocular Treatment-Emergent Adverse Events In the Study Eye

Table 38: Brolucizumab SWOT Analysis, 2017

Table 39: Product Profile – Abicipar Pegol

Table 40: Abicipar Pegol SWOT Analysis, 2017

Table 41: Product Profile – OPT-302

Table 42: OPT-302 SWOT Analysis, 2017

Table 43: Product Profile – Squalamine

Table 44: Squalamine SWOT Analysis, 2017

Table 45: Product Profile – Lampalizumab

Table 46: Lampalizumab SWOT Analysis, 2017

Table 47: Product Profile – Zimura

Table 48: Mean Visual Acuity in a Subgroup of Anti-VEGF-Naïve wAMD patients who Received Lucentis and Zimura

Table 49: Zimura SWOT Analysis, 2017

Table 50: Product Profile – APL-2

Table 51: APL-2 SWOT Analysis, 2017

Table 52: Product Profile – Brimo DDS

Table 53: Brimo DDS SWOT Analysis, 2017

Table 54: Innovative Early-Stage Approaches for AMD, 2017

Table 55: CNTO-2476 — Ocular Adverse Events Reported for All Surgical Subjects in the CNTO-2476 Phase I/IIa Study

Table 56: Drugs in Development for AMD, 2017

Table 57: Ranibizumab Biosimilars in Phase III of Development Within the 7MM, 2017

Table 58: Bevacizumab Biosimilars in Phase III of Development Within the 7MM, 2017

Table 59: Key Companies in the AMD Market in the 7MM, 2017

Table 60: Roche/Genentech’s AMD Portfolio Assessment, 2017

Table 61: Novartis/Alcon’s AMD Disease Portfolio Assessment, 2017

Table 62: Regeneron’s AMD Portfolio Assessment, 2017

Table 63: Bayer’s AMD Portfolio Assessment, 2017

Table 64: Valeant’s AMD Portfolio Assessment, 2017

Table 65: Allergan’s AMD Disease Portfolio Assessment, 2017

Table 66: Ohr’s AMD Portfolio Assessment, 2017

Table 67: Ophthotech’s AMD Portfolio Assessment, 2017

Table 68: Apellis’ AMD Portfolio Assessment, 2017

Table 69: Opthea’s AMD Portfolio Assessment, 2017

Table 70: AMD Market – Global Drivers and Barriers, 2016–2026

Table 71: Key Events Impacting Sales for AMD in the US, 2016–2026

Table 72: AMD Market – Drivers and Barriers in the US, 2016–2026

Table 73: Key Events Impacting Sales for AMD in the 5EU, 2016–2026

Table 74: AMD Market – Drivers and Barriers in the 5EU, 2016–2026

Table 75: Key Events Impacting Sales for AMD in Japan, 2016–2026

Table 76: AMD Market – Drivers and Barriers in Japan, 2016–2026

Table 77: Key Projected Launch Dates for AMD

Table 78: Key Projected Patent Expiry Dates for AMD

Table 79: High-Prescribing Physicians (non-KOLs) Surveyed, by Country

Figures

Figure 1: Global Sales Forecast by Country for AMD in 2016 and 2026

Figure 2: Company Portfolio Gap Analysis in AMD During the Forecast Period

Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to be Licensed for the Treatment of AMD During the Forecast Period

Figure 4: Anatomy of the Eye and Macula: Healthy, dAMD, and wAMD

Figure 5: 7MM, Age-Standardized Total Prevalence of AMD (%), Men and Women, Ages ≥50 Years, 2016

Figure 6: 7MM, Sources Used, Total Prevalent Cases of AMD, Early AMD, Late AMD, Late Dry AMD, Late Wet AMD, and Large Drusen

Figure 7: 7MM, Sources Used, Diagnosed Incident Cases of AMD, Early AMD, Late AMD, Late Dry AMD, Late Wet AMD, and Large Drusen

Figure 8: 7MM, Age-Specific Total Prevalent Cases of AMD, Both Sexes, N, 2016

Figure 9: 7MM, Sex-Specific Total Prevalent Cases of AMD, Ages ≥50 Years, N, 2016

Figure 10: 7MM, Age-Specific Diagnosed Incident Cases of AMD, Both Sexes, N, 2016

Figure 11: 7MM, Sex-Specific Diagnosed Incident Cases of AMD, Ages ≥50 Years, N, 2016

Figure 12: Amsler Grid, as Viewed by Patients with Normal Vision and with wAMD

Figure 13: Color Fundus Photographs of Dry and Wet AMD

Figure 14: FAF Imaging of GA

Figure 15: Imaging of wAMD

Figure 16: AMD Clinical Treatment Flowchart

Figure 17: Unmet Needs and Opportunities in AMD

Figure 18: Overview of the Development Pipeline in AMD

Figure 19: Key Phase II/III Trials for Promising Pipeline Agents for wAMD

Figure 20: Key Phase II/III Trials for the Promising Pipeline Agents for dAMD

Figure 21: Competitive Assessment of the Late-Stage Pipeline Agents

Figure 22: Clinical and Commercial Positioning of Brolucizumab

Figure 23: Clinical and Commercial Positioning of Abicipar Pegol

Figure 24: Clinical and Commercial Positioning of OPT-302

Figure 25: Clinical and Commercial Positioning of Squalamine

Figure 26: Clinical and Commercial Positioning of Lampalizumab

Figure 27: Clinical and Commercial Positioning of Zimura

Figure 28: Clinical and Commercial Positioning of APL-2.

Figure 29: Clinical and Commercial Positioning of Brimo DDS

Figure 30: Global Sales of Branded Products for AMD, by Company, 2016 and 2026

Figure 31: Company Portfolio Gap Analysis in AMD, 2016–2026

Figure 32: Global (7MM) Sales Forecast for AMD, by Country, 2016 and 2026

Figure 33: Global (7MM) Sales Forecast for AMD, by Country, 2016 and 2026

Figure 34: Individual Drug Sales for AMD in 2016 and 2026

Figure 35: Sales Forecast for AMD in the US, by Drug, 2016 and 2026

Figure 36: Sales Forecast by Drugs for AMD in the 5EU in 2016 and 2026

Figure 37: Sales Forecast for AMD in Japan, by Drug, 2016 and 2026

Frequently asked questions

PharmaPoint: Age-Related Macular Degeneration – Global Drug Forecast and Market Analysis to 2026 thematic reports
Currency USD
$10,995

Can be used by individual purchaser only

$32,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

PharmaPoint: Age-Related Macular Degeneration – Global Drug Forecast and Market Analysis to 2026 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at PharmaPoint: Age-Related Macular Degeneration – Global Drug Forecast and Market Analysis to 2026 in real time.

  • Access a live PharmaPoint: Age-Related Macular Degeneration – Global Drug Forecast and Market Analysis to 2026 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.